Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7617820 | 0.97 | LMNA (0.38) | LMNA | |
| SCHEMBL15486352 | 0.97 | LMNA (0.38) | LMNA | |
| SCHEMBL16333701 | 0.88 | LMNA (0.30) | LMNA | |
| SCHEMBL13856039 | 0.81 | — | — | |
| SCHEMBL503322 | 0.80 | LMNA (0.33) | LMNA | |
| SCHEMBL14204555 | 0.79 | — | — | |
| SCHEMBL29216669 | 0.79 | LMNA (0.31) | LMNA | |
| SCHEMBL13541921 | 0.78 | LMNA (0.38) | LMNA | |
| SCHEMBL16576084 | 0.78 | LMNA (0.38) | LMNA | |
| SCHEMBL16576097 | 0.78 | LMNA (0.38) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200246557-A1 | APPARATUS AND METHODS FOR PRODUCING AND DELIVERING A VAPOUR MEDICAMENT | SOLAEROMED INC. (CA) | 2020-08-06 | — | — | US | claimed |
| EP-3204097-A1 | APPARATUS AND METHODS FOR PRODUCING AND DELIVERING A VAPOUR MEDICAMENT | Solaeromed Inc. (CA) | 2017-08-16 | — | — | EP | claimed |
| WO-2016054742-A1 | APPARATUS AND METHODS FOR PRODUCING AND DELIVERING A VAPOUR MEDICAMENT | SOLAEROMED INC. (CA) | 2016-04-14 | — | — | WO | claimed |
| US-20160101246-A1 | APPARATUS AND METHODS FOR PRODUCING AND DELIVERING A VAPOUR MEDICAMENT | SOLAEROMED INC. (CA) | 2016-04-14 | — | — | US | claimed |
| US-20140213548-A1 | SYSTEM AND METHOD FOR HEMOSTATIC WOUND DRESSING | NEW JERSEY INSTITUTE OF TECHNOLOGY (US) | 2014-07-31 | — | — | US | claimed |
| US-20130316021-A1 | TREATMENT OF RESPIRATORY DISEASES | SOLAEROMED INC. (CA) | 2013-11-28 | — | — | US | claimed |
| US-8454938-B2 | Treatment of respiratory diseases | SOLAEROMED INC. (CA) | 2013-06-04 | — | — | US | claimed |
| EP-1962869-B1 | TREATMENT OF RESPIRATORY DISEASES | SOLAEROMED INC (CA) | 2013-03-20 | — | — | EP | claimed |
| US-7498169-B2 | Extending tissue preservation | UNIVERSITY OF SOUTH FLORIDA (US) | 2009-03-03 | — | — | US | claimed |
| EP-1962869-A1 | TREATMENT OF RESPIRATORY DISEASES | UTI Limited Partnership (CA) | 2008-09-03 | — | — | EP | claimed |
| US-20070190183-A1 | TREATMENT OF RESPIRATORY DISEASES | UTI LIMITED PARTNERSHIP (CA) | 2007-08-16 | — | — | US | claimed |
| WO-2007071052-A1 | TREATMENT OF RESPIRATORY DISEASES | UTI LIMITED PARTNERSHIP (CA) | 2007-06-28 | — | — | WO | claimed |
| JP-2006523507-A | — | — | 2006-10-19 | — | — | JP | claimed |
| EP-1631299-A2 | METHODS AND COMPOSITIONS TO TREAT MYOCARDIAL CONDITIONS | Guidant Corporation (US) | 2006-03-08 | — | — | EP | claimed |
| WO-2004091592-A2 | METHODS AND COMPOSITIONS TO TREAT MYOCARDIAL CONDITIONS | GUIDANT CORPORATION, V.I. (US) | 2004-10-28 | — | — | WO | claimed |
| US-20040208845-A1 | Delivering structurally reinforcing agents into a ventricle to increase compliance; prevention of remodeling and thinning of infarct zone by crosslinking collagen; pro-fibroblastic, antiischemic and angiogenic agents | ABBOTT CARDIOVASCULAR SYSTEMS INC. | 2004-10-21 | — | — | US | claimed |
| US-20040142466-A1 | Extending tissue preservation | UNIVERSITY OF SOUTH FLORIDA | 2004-07-22 | — | — | US | claimed |
| US-20260108886-A1 | MICROFLUIDIC DEVICES WITH PAIRING REGIONS AND DROPLET GENERATORS | HEWLETT PACKARD DEVELOPMENT CO (US) | 2026-04-23 | — | — | US | disclosed |
| WO-2007071052-A1 | TREATMENT OF RESPIRATORY DISEASES | UTI LIMITED PARTNERSHIP (CA) | 2007-06-28 | — | — | WO | disclosed |
| US-20040142466-A1 | Extending tissue preservation | UNIVERSITY OF SOUTH FLORIDA | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108886-A1 | MICROFLUIDIC DEVICES WITH PAIRING REGIONS AND DROPLET GENERATORS | PIEZO1, STIM1, AQP1 | LMNA 2300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.